The non-dilutive federal funding allows MyeloPro to maintain independence and provides resources in addressing the high medical need of rare, orphan blood malignancies called myelopoliferative neoplasms (MPNs).
MyeloPro is a discovery stage, Vienna (Austria) based biopharmaceutical company, developing therapeutics to treat myeloproliferative neoplasms. MyeloPro obtained a worldwide, exclusive therapeutic license from CeMM of the Austrian Academy of Science to target the mutant form of calreticulin (CALR). MyeloPro is actively seeking private investor partners for preclinical development of its most promising development candidates.
Oleh Zagrijtschuk, MD
Phone: +43 664 882 62 093